Arbutus and Assembly Bio have entered into a clinical collaboration agreement to evaluate a triple combination treatment with AB-729, Assembly Bio’s lead HBV core inhibitor vebicorvir (VBR), and standard-of-care nucleotide therapy in patients with chronic HBV.

Tags